Silencing Of Hmox1 Enhances Apoptosis Caused By Arsenic Trioxide In Hcc

Zhuoyang Fan,Jing He,Tong Fu,Lei Lv,Jianhua Wang
2019-01-01
Abstract:Arsenic trioxide (ATO) is an effective commercial chemotherapeutic drug used to treat different cancers. ATO can induce apoptosis in cancer cells by causing the accumulation of intracellular reactive oxygen species (ROS). However, the therapeutic effect of ATO on hepatocellular carcinoma (HCC) is unsatisfactory, largely due to chemoresistance. In this study, the antioxidant enzyme heme oxygenase 1 (HMOX1), whose function is to remove ROS, was found to be upregulated in SMMC-7721 cells after ATO intervention. The effect of knocking down HMOX1 on the effects of ATO treatment was also assessed. Cell viability, ROS concentrations, and apoptosis were examined in SMMC-7721 cells treated with or without ATO and transfected with or without HMOX1-siRNA. The results showed that HMOX1-siRNA downregulated HMOX1 expression in the presence of ATO. In addition, silencing of HMOX1 promoted ATO treatment-induced cell death by causing the accumulation of ROS and augmenting apoptosis. This study indicates that inhibition of HMOX1 could strengthen the therapeutic effect of ATO in hepatocellular carcinoma (HCC).
What problem does this paper attempt to address?